CIK 0001549595
- Large accelerated filer
Nurix Therapeutics, Inc.
Sign in to watch- Ticker
- NRIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Nov 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 270838048
- Phone
- +1 415-660-5320
- Business address
- 1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
- Former names
- Nurix, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,712,859
- in 10 filings, $1.0M under 10b5-1 plans
Net −$1,712,859. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 1 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-02-18 | Beaurang Pierre Chief Business Officer | Sale | −6,400 | $35.99 | $230K | 1,400 |
| 2021-02-18 | Beaurang Pierre Chief Business Officer | Sale | −1,000 | $36.92 | $37K | 400 |
| 2021-02-18 | Beaurang Pierre Chief Business Officer | Sale | −400 | $37.88 | $15K | 0 |
| 2021-02-18 | Beaurang Pierre Chief Business Officer | Exercise or conversion · Employee Stock Option (right to buy) | −9,107 | 14,226 | ||
| 2021-02-18 | Beaurang Pierre Chief Business Officer | Exercise or conversion · Employee Stock Option (right to buy) | −3,797 | 72,869 | ||
| 2021-02-18 | Beaurang Pierre Chief Business Officer | Exercise or conversion · Employee Stock Option (right to buy) | −2,096 | 14,678 | ||
| 2021-02-11 | van Houte Hans Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2021-02-11 | SANDS ARTHUR T President, CEO | Grant or award · Employee Stock Option (right to buy) | +150,000 | 150,000 | ||
| 2021-02-11 | Ring Christine General Counsel | Grant or award · Employee Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2021-02-11 | Hansen Gwenn Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2021-02-11 | Beaurang Pierre Chief Business Officer | Grant or award · Employee Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2021-02-04 | Third Rock Ventures III, L.P. 10% owner | Other disposition | −914,216 | 4,508,333 | ||
| 2020-11-30 | Hansen Gwenn Chief Scientific Officer | Exercise or conversion | +12,000 | $0.84 | $10K | 12,000 |
| 2020-11-30 | Hansen Gwenn Chief Scientific Officer | Exercise or conversion · Employee Stock Option (right to buy) | −12,000 | 31,333 | ||
| 2020-10-21 | SANDS ARTHUR T President, CEO | Grant or award · Stock Option (right to buy) | +804,170 | 804,170 | ||
| 2020-07-28 | Redmile Group, LLC 10% owner | Conversion | +1,176,470 | 1,176,470 | ||
| 2020-07-28 | Redmile Group, LLC 10% owner | Conversion · Series D Redeemable Convertible Preferred Stock | −1,176,470 | 0 | ||
| 2020-07-28 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner | Conversion | +784,313 | 784,313 | ||
| 2020-07-28 | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. 10% owner | Conversion · Series D Preferred Stock | −784,313 | 0 | ||
| 2020-07-28 | COLUMN GROUP L P 10% owner | Conversion | +600,000 | 683,333 |
Page 40 of 42 · 829 trades